Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 5.4 EUR Market Closed
Market Cap: 95.3m EUR

Vita 34 AG
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vita 34 AG
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Vita 34 AG
XETRA:V3V
Net Income (Common)
€2.6m
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
10%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Net Income (Common)
€718.2m
CAGR 3-Years
-2%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Fresenius SE & Co KGaA
XETRA:FRE
Net Income (Common)
€1.1B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Net Income (Common)
HK$76.5m
CAGR 3-Years
-13%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Net Income (Common)
€718.2m
CAGR 3-Years
-2%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
No Stocks Found

Vita 34 AG
Glance View

Market Cap
94.1m EUR
Industry
Health Care

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

V3V Intrinsic Value
HIDDEN
Show

See Also

What is Vita 34 AG's Net Income (Common)?
Net Income (Common)
2.6m EUR

Based on the financial report for Sep 30, 2024, Vita 34 AG's Net Income (Common) amounts to 2.6m EUR.

What is Vita 34 AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
10%

Back to Top